Allergen-specific immunotherapy induces regulatory T cells in an atopic dermatitis mouse model
Correction(s) for this article
-
Corrigendum
- Volume 74Issue 5Allergy
- pages: 1026-1026
- First Published online: May 16, 2019
J. U. Shin
Department of Dermatology & Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea
Search for more papers by this authorS. H. Kim
Department of Dermatology & Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea
Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea
Search for more papers by this authorJ. Y. Noh
Department of Dermatology & Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea
Search for more papers by this authorJ. H. Kim
Department of Dermatology & Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea
Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea
Search for more papers by this authorH. R. Kim
Department of Dermatology & Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea
Search for more papers by this authorK. Y. Jeong
Department of Internal Medicine, Institute of Allergy, Yonsei University College of Medicine, Seoul, Korea
Search for more papers by this authorK. H. Park
Department of Internal Medicine, Institute of Allergy, Yonsei University College of Medicine, Seoul, Korea
Search for more papers by this authorJ. Lee
Department of Dermatology & Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea
Search for more papers by this authorH. Chu
Department of Dermatology & Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea
Search for more papers by this authorJ.-H. Lee
Department of Internal Medicine, Institute of Allergy, Yonsei University College of Medicine, Seoul, Korea
Search for more papers by this authorT.-S. Yong
Department of Environmental Medical Biology, Arthropds of Medical Importance Resource Bank, Institute of Tropical Medicine, Yonsei University College of Medicine, Seoul, Korea
Search for more papers by this authorJ.-W. Park
Department of Internal Medicine, Institute of Allergy, Yonsei University College of Medicine, Seoul, Korea
Search for more papers by this authorCorresponding Author
K. H. Lee
Department of Dermatology & Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea
Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea
Correspondence
Kwang Hoon Lee, Department of Dermatology and Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea.
Email: [email protected]
Search for more papers by this authorJ. U. Shin
Department of Dermatology & Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea
Search for more papers by this authorS. H. Kim
Department of Dermatology & Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea
Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea
Search for more papers by this authorJ. Y. Noh
Department of Dermatology & Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea
Search for more papers by this authorJ. H. Kim
Department of Dermatology & Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea
Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea
Search for more papers by this authorH. R. Kim
Department of Dermatology & Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea
Search for more papers by this authorK. Y. Jeong
Department of Internal Medicine, Institute of Allergy, Yonsei University College of Medicine, Seoul, Korea
Search for more papers by this authorK. H. Park
Department of Internal Medicine, Institute of Allergy, Yonsei University College of Medicine, Seoul, Korea
Search for more papers by this authorJ. Lee
Department of Dermatology & Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea
Search for more papers by this authorH. Chu
Department of Dermatology & Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea
Search for more papers by this authorJ.-H. Lee
Department of Internal Medicine, Institute of Allergy, Yonsei University College of Medicine, Seoul, Korea
Search for more papers by this authorT.-S. Yong
Department of Environmental Medical Biology, Arthropds of Medical Importance Resource Bank, Institute of Tropical Medicine, Yonsei University College of Medicine, Seoul, Korea
Search for more papers by this authorJ.-W. Park
Department of Internal Medicine, Institute of Allergy, Yonsei University College of Medicine, Seoul, Korea
Search for more papers by this authorCorresponding Author
K. H. Lee
Department of Dermatology & Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea
Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea
Correspondence
Kwang Hoon Lee, Department of Dermatology and Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea.
Email: [email protected]
Search for more papers by this authorFunding information
This study was supported by a grant from the Ministry of Health & Welfare, Republic of Korea (grant number: HI14C1324).
Abstract
Background
Several studies have demonstrated that allergen-specific immunotherapy (SIT) can be an effective treatment for atopic dermatitis (AD). However, there is no relevant mouse model to investigate the mechanism and validate the novel modality of SIT in AD.
Methods
NC/Nga mice with induced AD-like skin lesions received a subcutaneous injection of SIT (an extract of the house dust mite Dermatophagoides farinae [DfE]) or placebo for 5 weeks). Clinical and histological improvements of AD-like skin lesions were examined. The responses of local and systemic regulatory T (Treg) cells, natural killer (NK) cells, B cells, serum immunoglobulin, and T-cell cytokine response to DfE were evaluated to determine the underlying mechanism of the observed results.
Results
Specific immunotherapy significantly improved AD-like skin lesions. Histologically, SIT decreased epidermal thickness and reduced inflammatory cell infiltration, especially that of eosinophils. Concomitantly, SIT suppressed Th2 responses and induced local infiltration of Treg cells into the skin. Also, SIT induced the immunoglobulin G4 and attenuated allergen-specific immunoglobulin E. Furthermore, SIT induced local and systemic IL-10-producing Treg cells and regulatory NK cells.
Conclusion
We established a SIT model on AD mice and showed that our model correlates well with previous reports about SIT-treated patients. Also, we revealed NK cells as another possible resource of IL-10 in SIT. Based on our results, we suggest our SIT model as a useful tool to investigate mechanism of action of SIT and to validate the efficacy of new SIT modalities for the treatment of AD.
CONFLICTS OF INTEREST
The authors declare that they have no conflicts of interest.
REFERENCES
- 1Arbes SJ Jr, Gergen PJ, Elliott L, Zeldin DC. Prevalences of positive skin test responses to 10 common allergens in the US population: results from the third National Health and Nutrition Examination Survey. J Allergy Clin Immunol. 2005; 116: 377-383.
- 2Durham SR, Leung DY. One hundred years of allergen immunotherapy: time to ring the changes. J Allergy Clin Immunol. 2011; 127: 3-7.
- 3Dolz I, Martinez-Cocera C, Bartolome JM, Cimarra M. A double-blind, placebo-controlled study of immunotherapy with grass-pollen extract Alutard SQ during a 3-year period with initial rush immunotherapy. Allergy. 1996; 51: 489-500.
- 4Varney VA, Hamid QA, Gaga M, et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest. 1993; 92: 644-651.
- 5Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev. 2007: Cd001936.
- 6Novak N, Bieber T, Hoffmann M, et al. Efficacy and safety of subcutaneous allergen-specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. J Allergy Clin Immunol. 2012; 130: 925-931.
- 7Bae JM, Choi YY, Park CO, Chung KY, Lee KH. Efficacy of allergen-specific immunotherapy for atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol. 2013; 132: 110-117.
- 8Lee J, Lee H, Noh S, et al. Retrospective analysis on the effects of house dust mite specific immunotherapy for more than 3 years in atopic dermatitis. Yonsei Med J. 2016; 57: 393-398.
- 9Lee J, Park CO, Lee KH. Specific immunotherapy in atopic dermatitis. Allergy Asthma Immunol Res. 2015; 7: 221-229.
- 10Akdis CA. Therapies for allergic inflammation: refining strategies to induce tolerance. Nat Med. 2012; 18: 736-749.
- 11Lou W, Wang C, Wang Y, Han D, Zhang L. Responses of CD4(+) CD25(+) Foxp3(+) and IL-10-secreting type I T regulatory cells to cluster-specific immunotherapy for allergic rhinitis in children. Pediatr Allergy Immunol. 2012; 23: 140-149.
- 12Suarez-Fueyo A, Ramos T, Galan A, et al. Grass tablet sublingual immunotherapy downregulates the TH2 cytokine response followed by regulatory T-cell generation. J Allergy Clin Immunol. 2014; 133: 130-138.
- 13Larche M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol. 2006; 6: 761-771.
- 14Durham SR, Varney VA, Gaga M, et al. Grass pollen immunotherapy decreases the number of mast cells in the skin. Clin Exp Allergy. 1999; 29: 1490-1496.
- 15Wilson DR, Irani AM, Walker SM, et al. Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium. Clin Exp Allergy. 2001; 31: 1705-1713.
- 16Rak S, Heinrich C, Jacobsen L, Scheynius A, Venge P. A double-blinded, comparative study of the effects of short preseason specific immunotherapy and topical steroids in patients with allergic rhinoconjunctivitis and asthma. J Allergy Clin Immunol. 2001; 108: 921-928.
- 17Kay AB. Allergy and allergic diseases. Second of two parts. N Engl J Med. 2001; 344: 109-113.
- 18Kay AB. Allergy and allergic diseases. First of two parts. N Engl J Med. 2001; 344: 30-37.
- 19Drachenberg KJ, Wheeler AW, Stuebner P, Horak F. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy. 2001; 56: 498-505.
- 20Mothes N, Heinzkill M, Drachenberg KJ, et al. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy. 2003; 33: 1198-1208.
- 21Flicker S, Steinberger P, Norderhaug L, et al. Conversion of grass pollen allergen-specific human IgE into a protective IgG(1) antibody. Eur J Immunol. 2002; 32: 2156-2162.
- 22Visco V, Dolecek C, Denepoux S, et al. Human IgG monoclonal antibodies that modulate the binding of specific IgE to birch pollen Bet v 1. J Immunol. 1996; 157: 956-962.
- 23van de Veen W, Stanic B, Yaman G, et al. IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses. J Allergy Clin Immunol. 2013; 131: 1204-1212.
- 24Deniz G, van de Veen W, Akdis M. Natural killer cells in patients with allergic diseases. J Allergy Clin Immunol. 2013; 132: 527-535.
- 25Janssen EM, van Oosterhout AJ, Nijkamp FP, van Eden W, Wauben MH. The efficacy of immunotherapy in an experimental murine model of allergic asthma is related to the strength and site of T cell activation during immunotherapy. J Immunol. 2000; 165: 7207-7214.
- 26Maazi H, Shirinbak S, Willart M, et al. Contribution of regulatory T cells to alleviation of experimental allergic asthma after specific immunotherapy. Clin Exp Allergy. 2012; 42: 1519-1528.
- 27Taher YA, van Esch BC, Hofman GA, Henricks PA, van Oosterhout AJ. 1alpha,25-dihydroxyvitamin D3 potentiates the beneficial effects of allergen immunotherapy in a mouse model of allergic asthma: role for IL-10 and TGF-beta. J Immunol. 2008; 180: 5211-5221.
- 28Bohm L, Maxeiner J, Meyer-Martin H, et al. IL-10 and regulatory T cells cooperate in allergen-specific immunotherapy to ameliorate allergic asthma. J Immunol. 2015; 194: 887-897.
- 29Yamamoto M, Haruna T, Yasui K, et al. A novel atopic dermatitis model induced by topical application with dermatophagoides farinae extract in NC/Nga mice. Allergol Int. 2007; 56: 139-148.
- 30Matsuoka H, Maki N, Yoshida S, et al. A mouse model of the atopic eczema/dermatitis syndrome by repeated application of a crude extract of house-dust mite Dermatophagoides farinae. Allergy. 2003; 58: 139-145.
- 31Kim JY, Jeong MS, Park MK, Lee MK, Seo SJ. Time-dependent progression from the acute to chronic phases in atopic dermatitis induced by epicutaneous allergen stimulation in NC/Nga mice. Exp Dermatol. 2014; 23: 53-57.
- 32Kang JS, Lee K, Han SB, et al. Induction of atopic eczema/dermatitis syndrome-like skin lesions by repeated topical application of a crude extract of Dermatophagoides pteronyssinus in NC/Nga mice. Int Immunopharmacol. 2006; 6: 1616-1622.
- 33Ewald DA, Noda S, Oliva M, et al. Major differences between human atopic dermatitis and murine models, as determined by using global transcriptomic profiling. J Allergy Clin Immunol. 2017; 139: 562-571.
- 34Jeong KY, Choi SY, Lee JH, et al. Standardization of house dust mite extracts in Korea. Allergy Asthma Immunol Res. 2012; 4: 346-350.
- 35Jeong KY, Choi SY, Han IS, et al. The effects of storage conditions on the stability of house dust mite extracts. Allergy Asthma Immunol Res. 2013; 5: 397-401.
- 36Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med. 1999; 341: 468-475.
- 37Golden DB, Kagey-Sobotka A, Norman PS, Hamilton RG, Lichtenstein LM. Outcomes of allergy to insect stings in children, with and without venom immunotherapy. N Engl J Med. 2004; 351: 668-674.
- 38Fujita H, Soyka MB, Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy. Clin Transl Allergy. 2012; 2: 2.
- 39Nouri-Aria KT, Wachholz PA, Francis JN, et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol. 2004; 172: 3252-3259.
- 40Reisinger J, Horak F, Pauli G, et al. Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity. J Allergy Clin Immunol. 2005; 116: 347-354.
- 41Radulovic S, Jacobson MR, Durham SR, Nouri-Aria KT. Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. J Allergy Clin Immunol. 2008; 121: 1467-1472.
- 42Mobs C, Slotosch C, Loffler H, Jakob T, Hertl M, Pfutzner W. Birch pollen immunotherapy leads to differential induction of regulatory T cells and delayed helper T cell immune deviation. J Immunol. 2010; 184: 2194-2203.
- 43Ebner C, Siemann U, Bohle B, et al. Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen. Clin Exp Allergy. 1997; 27: 1007-1015.
- 44Secrist H, Chelen CJ, Wen Y, Marshall JD, Umetsu DT. Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals. J Exp Med. 1993; 178: 2123-2130.
10.1002/eji.1830270513 Google Scholar
- 45Maggi E, Vultaggio A, Matucci A. T-cell responses during allergen-specific immunotherapy. Curr Opin Allergy Clin Immunol. 2012; 12: 1-6.
- 46Francis JN, Till SJ, Durham SR. Induction of IL-10+ CD4+ CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol. 2003; 111: 1255-1261.
- 47Tarzi M, Klunker S, Texier C, et al. Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy. Clin Exp Allergy. 2006; 36: 465-474.
- 48Akdis CA, Blesken T, Akdis M, Wuthrich B, Blaser K. Role of interleukin 10 in specific immunotherapy. J Clin Invest. 1998; 102: 98-106.
- 49Akdis M, Verhagen J, Taylor A, et al. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med. 2004; 199: 1567-1575.
- 50Jutel M, Akdis M, Budak F, et al. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol. 2003; 33: 1205-1214.
- 51Ling EM, Smith T, Nguyen XD, et al. Relation of CD4+ CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet. 2004; 363: 608-615.
10.1111/j.1365-2222.2004.02067.x Google Scholar
- 52Royer B, Varadaradjalou S, Saas P, Guillosson JJ, Kantelip JP, Arock M. Inhibition of IgE-induced activation of human mast cells by IL-10. Clin Exp Allergy. 2001; 31: 694-704.
- 53Schandene L, Alonso-Vega C, Willems F, et al. B7/CD28-dependent IL-5 production by human resting T cells is inhibited by IL-10. J Immunol. 1994; 152: 4368-4374.
- 54Jeannin P, Lecoanet S, Delneste Y, Gauchat JF, Bonnefoy JY. IgE versus IgG4 production can be differentially regulated by IL-10. J Immunol. 1998; 160: 3555-3561.
- 55Yanaba K, Bouaziz JD, Haas KM, Poe JC, Fujimoto M, Tedder TF. A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity. 2008; 28: 639-650.
- 56Mauri C, Bosma A. Immune regulatory function of B cells. Annu Rev Immunol. 2012; 30: 221-241.
- 57Kalampokis I, Yoshizaki A, Tedder TF. IL-10-producing regulatory B cells (B10 cells) in autoimmune disease. Arthritis Res Ther. 2013; 15(suppl 1): S1.
- 58Li J, Shen C, Liu Y, et al. Impaired Function of CD5+ CD19+ CD1dhi B10 Cells on IgE secretion in an atopic dermatitis-like mouse model. PLoS One. 2015; 10: e0132173.
Citing Literature
